Cholangiocarcinoma

Agios Announces Primary Endpoint Reached in Phase 3 ClarIDHy Trial of Tibsovo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

May 18, 2019 | Cholangiocarcinoma, Positive Results

Agios Pharmaceuticals announced that the global Phase 3 ClarIDHy trial of Tibsovo (ivosidenib) in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 (IDH1) mutation met its primary endpoint. Treatment with Tibsovo demonstrated a...

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

159 WEST BROADWAY SUITE 200
SALT LAKE CITY, UT 84101

Agios Announces Primary Endpoint Reached in Phase 3 ClarIDHy Trial of Tibsovo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

Pin It on Pinterest